2 edition of Studies on tissue plasminogen activator and its inhibitor in human saliva found in the catalog.
Studies on tissue plasminogen activator and its inhibitor in human saliva
Thesis (Ph.D.)--Dept. of Cariology, School of Dentistry, Karolinska Institutet, Stockholm, 1991.
|Statement||by Marianne Kjaeldgaard.|
Recombinant Human Tissue Plasminogen Activator produced inCHO cellsis a single, glycosylated polypeptide chain containing amino acids and having a molecular mass of Dalton. TPA is a serine protease enzyme that converts plasminogen to plasmin. Tissue-type Plasminogen Activator Deﬁciency Exacerbates Cholestatic Liver Injury in Mice HongtaoWang,1 YanZhang,2,3 roth1 Recent studies demonstrating a role for plasminogen activator inhibitor (PAI)-1 in choles-tatic liver disease in mice suggested that tissue-type plasminogen activator (tPA) or uroki-Cited by:
Tissue plasminogen activator (tPA) is the only approved thrombolytic therapy for acute ischemic stroke. Early recanalization of occluded vessels is associated with improved clinical outcome, yet less than 50% of all stroke patients treated intravenously with tPA will successfully recanalize the setting of carotid artery occlusion, tPA is even less effective, with recanalization rates of Cited by: 5. The older methods such as dilute blood clot lysis or euglobulin clot lysis measure overall fibrinolytic activity, which is dependent on plasminogen activator level, both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), plasminogen level, the levels of inhibitors of plasminogen activators such as PAI-1 Cited by: 1.
INTRODUCTION. Tissue plasminogen activator (t-PA) 1 is a serine protease playing the dominant role in elimination of fibrin from the vasculature by activating the circulating zymogen, plasminogen, to the primary fibrinolytic enzyme, plasmin (1, 2).The major source of circulating t-PA under basal conditions is thought to be the endothelial cell (3, 4). Recombinant tissue plasminogen activator (tPA) is widely to treat thrombotic disorders such as acute ischemic stroke, deep venous thrombosis .As a result, there is much interest in optimizing lytic therapy using tPA in the treatment of such disease .Such optimization requires substantial in-vitro and in-vivo  ore the preservation of tPA for laboratory use in such studies is of Cited by:
An examination of some aspects of the unit-load system of cargo shipments
Spirit above wars
France and the United States
Supplement to annals of the American Academy of Political and Social Science. January, 1893. Constitution of the Republic of Colombia, with an historical introduction.
Aberconwy draft local plan, May 1996.
Drug laws and institutional racism
Contemplation in Aristotle.
H.R. 2891, to preserve the continued viability of the United States air transportation system
Institute of Pacific Relations.
From symmetries to strings
Reasons vvhy the hierarchy or governement of the church by arch-bishops, lord bishops, deanes, arch-deacons, chancelors and their officers exercising sole or superiour authoritie in ordinations and jurisdictions may and ought to be removed
letter from Mr. MacCartney, to a friend of his in London. Dated at Ostend, Dec. 4-15. 1712
Provides accurate and independent information on more t prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Data sources include IBM Watson Micromedex (updated 4 May ), Cerner Multum™ (updated 4 May ), Wolters Kluwer™. The fibrinolytic system (Figure ) comprises an inactive proenzyme, plasminogen, which can be converted to the active enzyme, plasmin, which in turn degrades fibrin into soluble fibrin degradation physiological plasminogen activators have been identified: the tissue-type activator, recommended by NC-IUBMB to be called t-plasminogen activator (t-PA) and the urokinase-type, u.
In the present study, mixed fresh human saliva was found to contain an inhibitor for tissue plasminogen activator and for urokinase. The plasminogen activator inhibitory activity was mainly found in the mixed fresh human saliva cellular pellet containing buccal epithelial cells and not Cited by: 3.
Tissue plasminogen activator (tPA, tissue-type plasminogen activator) is a serine protease found on endothelial cells (cells that line the blood vessels) involved in the breakdown of blood clots (fibrinolysis). tPA enzyme catalyzes the conversion of plasminogen to.
Since a pioneer work that has shown in vitro that the rat's fibrinolytic system is fold less sensitive to recombinant tissue-plasminogen activator (rtPA) than the human system, most preclinical studies are performed with 10 instead of mg/kg rtPA (the clinical dose in stroke patients).
In this study, we compared the effects of these doses on mean time to reperfusion, reperfusion slope Cited by: 1 Introduction.
Tissue plasminogen activator (t-PA) is a glycoprotein produced mainly by vascular endothelial cells. 1,2 It activates clot dissolution in the presence of fibrin by conversion of plasminogen to plasmin, thereby cleaving cross-linked fibrin to D-dimer and other degradation products, 3 and it may also be involved in coronary plaque rupture.
2 As free active t-PA is difficult to Cited by: Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or serpin E1 is a protein that in humans is encoded by the SERPINE1 ed PAI-1 is a risk factor for thrombosis and atherosclerosis.
PAI-1 is a serine protease inhibitor that functions as the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of Aliases: SERPINE1, PAI, PAI-1, PAI1, PLANH1. Wing LR, Bennett B, Booth NA. The receptor for tissue plasminogen activator (t-PA) in complex with its inhibitor, PAI-1, on human hepatocytes.
FEBS Lett. Jan 14; (1)– Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination.
Br J by: Human tissue plasminogen activator (t-PA) was shown to bind specifically to human osteosarcoma cells (HOS), and human epidermoid carcinoma cells (A cells). Human tissue-type plasminogen activator (tPA) is a valuable thrombolytic agent used to successfully treat acute myocardial infarction, thromboembolic stroke, peripheral arterial occlusion, and.
Maybe a second Major Heading further down the page "Alteplase: recombinant Tissue Plasminogen Activator" and a wikiproject drugs format be followed there.
I suggest that this will become of increasing importance as more recombiinant drugs appear, and new drugs like alteplase may carry a different moniker than the endogenous protein. 0 by The American Society of Biological THE JOURNAL OF BIOLOGICAL CHEMISTRY Chemists, Inc.
Vol.No. 15, Issue of pp.Printed in U.S.A. The Human Tissue Plasminogen Activator Gene* (Received for publication, Septem) Sandra J. Friezner Degeng, Bhanu Rajput, and E. Reich§. Human tissue plasminogen activator has been used to study the effect of tyrosinase-related protein 2 (TRP-2) expression on melanin production in sheep.
Biochem/physiol Actions tPA is a potent activator of fibrinolysis and converts plasminogen into plasmin and also initiates cell signaling. Tissue Plasminogen Activator Subject Areas on Research 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial.
tissue plasminogen activator: [ ak´tĭ-va″ter ] a substance that makes another substance active or reactive, induces a chemical reaction, or combines with an enzyme to increase its catalytic activity.
plasminogen activator a substance that activates plasminogen and converts it into plasmin ; see t-plasminogen activator and u-plasminogen.
Native tissue plasminogen activator from a human melanoma cell line. A serine protease that contains a single chain of amino acids. Binds to fibrin via lysine binding sites at its amino terminus and activates bound plasminogen.
Cleaves plasminogen to form active plasmin, the. Learn tissue plasminogen activator (TPA) with free interactive flashcards. Choose from 38 different sets of tissue plasminogen activator (TPA) flashcards on Quizlet. Plasminogen is the precursor of plasmin, which lyses fibrin clots to fibrin degradation products (FDP) and D-dimer; the conversion to active protease is mediated by tissue-type (tPA) and urokinase-type (uPA) plasminogen activators.
Generated plasmin is quickly inactivated by its main inhibitor alpha2-antiplasmin. [1, 2, 3]. It is well known that fibrinolytic activity in the early stages of acute experimental pancreatitis (AEP) as assessed by euglobulin lysis time (ELT) is depressed.
The aim of this study was to evaluate changes in the fibrinolytic system in the early stages of taurocholate AEP in rats. Tissue plasminogen activator (t-PA) activity, plasminogen activator inhibitor 1 (PAI-1) activity, plasminogen Cited by: To test the efficacy of the recombinant tissue-type plasminogen activator (rt-PA) alteplase in horses, the thrombolytic effect was tested in in vitro generated equine thrombi.
The extent of lysis was determined by measuring the decrease in thrombi weight over a period of 4 hours. In vivo pharmacokinetics of alteplase were determined in 6 healthy by: 4.
Characterization of a plasminogen activator and its inhibitor in human mesangial cells. In the course of some pathological and experimental nephropathies, intragiomerular fibrin deposits develop, possibly as a consequence of inefficient fibrinolysis.
In vitro human glomeruli exhibit fibrinolytic activity due to the synthesis of plasminogen.Lin L, Wu C, Hu K. Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked kinase. J Am Soc Nephrol.
; Vivien D, Gauberti M, Montagne A, Defer G, Touzé E. Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. Isolated Sertoli cells of mouse and rat testes have been shown to secrete plasminogen activator (PA) and a plasminogen activator inhibitor type-1 (PAI-1) in culture.
In this study, we have investigated the hormonal regulation of PA and PAI-1 activities in cultured monkey Sertoli by: 1.